Hikma signs on to sell Theravance's Vibativ; Sanofi nabs Japanese nod for Lyxumia;

 @FiercePharma: Fresenius Kabi yanks four lots of benztropine mesylate on risk of glass particles, stops distribution to investigate. News | Follow @FiercePharma

 @EricPFierce: ICYMI: FDA approves first non-hormonal treatment for hot flashes. Release | Follow @EricPFierce

> Hikma Pharmaceuticals inked a deal to commercialize Theravance's ($THRX) treatment for drug-resistant staph infections, Vibativ, in the Middle East and Africa. Release

> Sanofi ($SNY) won Japanese approval for its new diabetes drug Lyxumia; its application for U.S. approval is still pending. Report

> GlaxoSmithKline ($GSK) moved 150 research projects back to the U.K. to take advantage of the new "patent box" tax rate of 10%. Report

> Fresenius Kabi's U.S. unit recalled four lots of its benztropine mesylate injection on the possibility of glass particles in drug vials and stopped distributing the products pending an investigation. Report

> India's Aurobindo Pharma signed a deal with the Medicines Patent Pool to produce medicines for treating children with HIV. Report

> Pharming agreed to collaborate with a Sinopharm subsidiary on selling the Dutch biotech's angioedema drug Ruconest/Rhucin and developing other treatments. Report

Medical Device News

 @FierceMedDev: Veracyte nails $28M Series C. Story | Follow @FierceMedDev

 @MarkHFierce: There's still time to submit your nomination for this year's FMD Fierce 15. More | Follow @MarkHFierce

 @DamianFierce: Thoratec is spending up to $56.5M for Terumo's in-development heart device. News | Follow @DamianFierce

> Malaysia's new device regs poised to heighten the competition. Article

> A drug-free Covidien is now all about devices. Story

> Zyomyx pulls in $12M to advance low-cost HIV Dx to finish line. More

Biotech News

 @FierceBiotech: Insmed shares routed on head-to-head antibiotic Phase III results. Story | Follow @FierceBiotech

 @JohnCFierce: The FDA's suvorexant decision was expected. I don't see how weak suvo competes with the generics. It'll be an alternative for non-response. | Follow @JohnCFierce

 @RyanMFierce: Onyx is following the M&A resistance strategy, which Termeer and more recently Martin have used. More | Follow @RyanMFierce

> FDA scraps Merck's high-dose sleep drug, demands weaker version. Story

> Report: China rounds up GlaxoSmithKline staffers in corruption probe. Article

CRO News

> MMS teams up with Datatrak for eClinical heft. Story

> Want to work with Roche? Prepare for high standards. More

> AstraZeneca taps Sarah Cannon for cancer R&D. Article

Biotech IT News

> Ex-Googlers bring Big Data analytics to oncology. News

> Deloitte turns EHR reservoir into health outcomes tool. Article

> J&J teams up with Mount Sinai on bioinformatics project. Story

> Data secrecy and outdated tech exacerbating drug shortages. More

And Finally... The World Health Organization called for earlier treatment of patients diagnosed with HIV infection; under new guidelines, 26 million patients would need treatment worldwide. Report

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."